Kalbe Farma Tbk PT
IDX:KLBF

Watchlist Manager
Kalbe Farma Tbk PT Logo
Kalbe Farma Tbk PT
IDX:KLBF
Watchlist
Price: 1 400 IDR 5.26%
Market Cap: 65.6T IDR
Have any thoughts about
Kalbe Farma Tbk PT?
Write Note

Kalbe Farma Tbk PT
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Kalbe Farma Tbk PT
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Kalbe Farma Tbk PT
IDX:KLBF
Current Portion of Long-Term Debt
Rp86.8B
CAGR 3-Years
26%
CAGR 5-Years
24%
CAGR 10-Years
N/A
T
Tempo Scan Pacific Tbk PT
IDX:TSPC
Current Portion of Long-Term Debt
Rp37.5B
CAGR 3-Years
-1%
CAGR 5-Years
18%
CAGR 10-Years
50%
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
Current Portion of Long-Term Debt
Rp443.6m
CAGR 3-Years
-77%
CAGR 5-Years
-61%
CAGR 10-Years
-34%
Soho Global Health Tbk PT
IDX:SOHO
Current Portion of Long-Term Debt
Rp10.5B
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pyridam Farma Tbk PT
IDX:PYFA
Current Portion of Long-Term Debt
Rp66.4B
CAGR 3-Years
111%
CAGR 5-Years
147%
CAGR 10-Years
28%
Kimia Farma Tbk PT
IDX:KAEF
Current Portion of Long-Term Debt
Rp1.1T
CAGR 3-Years
12%
CAGR 5-Years
54%
CAGR 10-Years
91%
No Stocks Found

Kalbe Farma Tbk PT
Glance View

Market Cap
64.6T IDR
Industry
Pharmaceuticals

Kalbe Farma Tbk PT is a renowned pharmaceutical powerhouse rooted in Indonesia, rooted in a rich history that traces back to 1966. The company has evolved from a humble startup into a multifaceted entity with a robust portfolio, making it a vital player in the health and wellness sector across Southeast Asia. The company operates across four main business divisions: prescription pharmaceuticals, consumer health products, nutritionals, and distribution & logistics. By strategically linking these divisions, Kalbe Farma masterfully balances scientific innovation with market accessibility, ensuring a wide reach and varied product offering. This diversification not only broadens its revenue streams but also mitigates risk, securing its foothold in the competitive pharmaceutical landscape. At the core of Kalbe Farma’s business model lies a commitment to research and development, which fuels its cutting-edge product innovations and enhances its competitive edge. The company dedicates substantial resources to developing new medicines and health products, constantly seeking to address emerging health concerns. Moreover, its extensive distribution network fortifies its market presence, comprising a domestic distribution arm that penetrates even the farthest reaches of the Indonesian archipelago. This network ensures that Kalbe's products are widely available, amplifying their market penetration and revenue. Additionally, Kalbe embraces partnerships and collaborations to enhance its research capabilities and expand its product offerings, fostering an ecosystem where innovation and accessibility coexist harmoniously, thereby empowering its bottom line.

KLBF Intrinsic Value
1 429.6 IDR
Undervaluation 2%
Intrinsic Value
Price

See Also

What is Kalbe Farma Tbk PT's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
86.8B IDR

Based on the financial report for Sep 30, 2024, Kalbe Farma Tbk PT's Current Portion of Long-Term Debt amounts to 86.8B IDR.

What is Kalbe Farma Tbk PT's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
24%

Over the last year, the Current Portion of Long-Term Debt growth was -42%. The average annual Current Portion of Long-Term Debt growth rates for Kalbe Farma Tbk PT have been 26% over the past three years , 24% over the past five years .

Back to Top